Information Provided By: 
Fly News Breaks for August 3, 2016
SPNC
Aug 3, 2016 | 05:35 EDT
UBS analyst Matt Miksic double upgraded Spectranetics to Buy from Sell and tripled his price target for the shares to $30 from $10. The company's Q2 results showed stabilization of the core Vascular Intervention businesses for peripheral and coronary intervention, clearing the way for the Stellarex drug-coated balloon platform to take over as the central value driver for the stock, Miksic tells investors in a post-earnings research note. The analyst projects 26% market share for Stellarex in 2020 on "strong clinical data."
News For SPNC From the Last 2 Days
There are no results for your query SPNC
